Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group

Publication | Closed Access

DOI

126

Citations

References

2018

Year

Hans Wildiers, Konstantinos Tryfonidis, Lissandra Dal Lago, Peter Vuylsteke, Giuseppe Curigliano, Simon Waters, Barbara Brouwers, Sevilay Altıntaş, Nathan Touati, Fátima Cardoso,

The Lancet Oncology

Breast OncologyOncologyMetronomic TherapyBreast CancerMetronomic ChemotherapyCancer TreatmentMedicineRadiation OncologyOlder PatientsEortc 75111-10114